[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 9449
1. Khaykin Y, Skanes A, Wulffhart ZA, Gula L, Whaley B, Oosthuizen R, Seabrook C, Beardsall M, Verma A: Intracardiac ECHO Integration with Three Dimensional Mapping: Role in AF Ablation. J Atr Fibrillation; 2008 Jul-Aug;1(2):32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary veins and the esophagus were rendered in 3D.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Electrophysiol. 2007 Mar;18(3):276-82 [17284265.001]
  • [Cites] Circulation. 1999 Sep 14;100(11):1203-8 [10484541.001]
  • [Cites] J Cardiovasc Electrophysiol. 2004 Nov;15(11):1335-40 [15574190.001]
  • [Cites] Circ Arrhythm Electrophysiol. 2008 Jun 1;1(2):110-9 [19808401.001]
  • [Cites] J Am Coll Cardiol. 2002 Aug 7;40(3):464-74 [12142112.001]
  • [Cites] Heart Rhythm. 2007 May;4(5):595-602 [17467627.001]
  • [Cites] Circulation. 2000 Nov 21;102(21):2619-28 [11085966.001]
  • (PMID = 28496579.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Shaheen N: Barrett Esophagus: Disease Management and Patient Perceptions. Gastroenterol Hepatol (N Y); 2006 Jul;2(7):468-470

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett Esophagus: Disease Management and Patient Perceptions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7290-5 [16437630.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4478-82 [16002837.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):429-36 [16083700.001]
  • (PMID = 28289347.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ginsberg G: Endoluminal Therapies for Barrett's Esophagus and Dysplasia. Gastroenterol Hepatol (N Y); 2006 Mar;2(3):165-167

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoluminal Therapies for Barrett's Esophagus and Dysplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):241-5 [15017662.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):258-63 [15017666.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • (PMID = 28286444.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Badylak SF, Kochupura PV, Cohen IS, Doronin SV, Saltman AE, Gilbert TW, Kelly DJ, Ignotz RA, Gaudette GR: The Use of Extracellular Matrix as an Inductive Scaffold for the Partial Replacement of Functional Myocardium. Cell Transplant; 2006 Jan;15(1_suppl):29-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECM scaffolds have been shown to support constructive remodeling of other tissue types including the lower urinary tract, the dermis, the esophagus, and dura mater by mechanisms that include the recruitment of bone marrow-derived progenitor cells, angiogenesis, and the generation of bioactive molecules that result from degradation of the ECM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863772.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioscaffold / Extracellular matrix / Myocardium / Regenerative medicine / Tissue engineering / Urinary bladder matrix
  •  go-up   go-down


5. St-Hilaire J, Lavoie C, Beaulieu F, Dagnault A, Morin F, Gingras L, Tremblay D, Beaulieu L: Sci-Fri PM: Planning-04: Dose escalation study using anatomy-based aperture IMRT and SPECT perfusion images for lung cancer. Med Phys; 2008 Jul;35(7Part3):3412-3413

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of non-small cell lung cancer, doses typically prescribed (60-66 Gy) are not sufficient to ensure a satisfactory tumor control probability.
  • Escalation was limited in two cases by the dose to the esophagus and in the other case by the presence of overdosages near beam entry ports.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512890.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Intensity modulated radiation therapy / Lungs / Medical imaging / Photons / Single photon emission computed tomography / Spatial analysis / Spatial dimensions
  •  go-up   go-down


6. Rastogi A, Sharma P: Short-Segment Barrett's Esophagus and Adenocarcinoma. Gastroenterol Hepatol (N Y); 2006 Feb;2(2):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-Segment Barrett's Esophagus and Adenocarcinoma.
  • Barrett's esophagus is a known risk factor for the development of adenocarcinoma of the esophagus and esophagogastric junction.
  • Based on the length of the columnar segment at endoscopy, Barrett's esophagus has been arbitrarily separated into two broad categories: long-segment and short-segment.
  • The rapid rise in the incidence of esophageal adenocarcinoma has generated sustained research interest in this lesion.
  • Studies have shown that although the prevalence of short-segment Barrett's esophagus is higher than that of long-segment Barrett's esophagus, the risk of developing dysplasia and adenocarcinoma may actually be lower in those patients with short segment Barrett's esophagus.
  • Nonetheless, both dysplasia and esophageal adenocarcinoma have been reported in patients with short-segment Barrett's esophagus, making this arbitrary distinction clinically unimportant.
  • The current surveillance guidelines remain the same for both short- and long-segment Barrett's esophagus.
  • Another key issue is differentiating short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia.
  • The latter is distinct from esophageal intestinal metaplasia (ie, Barrett's esophagus) and probably does not warrant surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastrointest Endosc. 1987 Dec;33(6):413-6 [3443258.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):913-8 [10201456.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1378-82 [11374671.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):652-4 [8119225.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Ann Intern Med. 2000 Apr 18;132(8):612-20 [10766679.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):597-602 [9073145.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):554-65 [6625723.001]
  • [Cites] Gut. 1997 Jun;40(6):710-5 [9245922.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):87-94 [11145256.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1996 Aug;91(8):1507-11 [8759651.001]
  • [Cites] Gut. 2000 Jan;46(1):9-13 [10601047.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Gastrointest Endosc. 1994 Jan-Feb;40(1):111 [8163114.001]
  • [Cites] Gut. 1998 Jul;43(1):17-21 [9771400.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):603-7 [9073146.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):670-80 [8172136.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):981-6 [8633592.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92(11):2012-6 [9362182.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):407-13 [9068459.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • (PMID = 28286441.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Barrett’s esophagus / adenocarcinoma / high-grade dysplasia / long-segment Barrett’s esophagus / low-grade dysplasia / short-segment Barrett’s esophagus
  •  go-up   go-down


7. Lim EJ, Stella DL, Russell DM: Torrential upper gastrointestinal bleeding from 'downhill' oesophageal varices complicating long term central venous access for total parenteral nutrition. Frontline Gastroenterol; 2010 Jul;1(2):118-120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torrential upper gastrointestinal bleeding from 'downhill' oesophageal varices complicating long term central venous access for total parenteral nutrition.
  • Oesophageal varices usually develop in the setting of portal hypertension secondary to chronic liver disease.
  • However, superior vena cava (SVC) obstruction can result in 'downhill' varices forming in the upper oesophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Nephrol. 2008 Oct;12(5):407-15 [18401548.001]
  • [Cites] Dig Dis Sci. 1982 Jan;27(1):23-7 [6978238.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1010-2 [18436214.001]
  • [Cites] Eur J Intern Med. 2006 Dec;17(8):586 [17142183.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Nov;29(11):1484-8 [1663180.001]
  • [Cites] Neurology. 1996 Oct;47(4):1081-5 [8857750.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):1863, 2158 [19013160.001]
  • [Cites] Dis Chest. 1964 Dec;46:740-6 [14248507.001]
  • [Cites] Dtsch Med Wochenschr. 1998 May 29;123(22):691-5 [9645185.001]
  • (PMID = 28839559.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Somerville M, Pitt M: Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile? Frontline Gastroenterol; 2010 Jul;1(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?
  • In 2004, the Peninsula Technology Assessment Group developed an economic model to assess the effectiveness and cost effectiveness of surveillance of Barrett's oesophagus in preventing morbidity and mortality from oesophageal adenocarcinoma.
  • At present, there seems little reason to change our original conclusion that surveillance of Barrett's oesophagus is unlikely to be cost effective and a definitive answer may only be possible from clinical trials now in progress.
  • As newer endoscopic techniques for treating Barrett's oesophagus and adenocarcinoma become more widely used, however, conventional surveillance programmes may no longer be undertaken, and revised economic models will be needed to assess the cost effectiveness of the new clinical pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):868-79 [15476150.001]
  • [Cites] Histopathology. 2009 Jun;54(7):814-9 [19635100.001]
  • [Cites] Endoscopy. 2009 May;41(5):400-8 [19418393.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1340-5 [18510606.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Health Qual Life Outcomes. 2006 Nov 27;4:90 [17129380.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23 [19281858.001]
  • [Cites] Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv [16545207.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • (PMID = 28839554.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


9. Ragan D, Starkschall G, McNutt T, Kaus M, Guerrero T, Stevens CW: Semiautomated four-dimensional computed tomography segmentation using deformable models. Med Phys; 2005 Jul;32(7Part1):2254-2261

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The contours of the right and left lungs, cord, heart, and esophagus were manually delineated on the end inspiration data set.
  • The algorithm failed to accurately contour the esophagus, a soft-tissue structure completely surrounded by tissue of similar density, without manual interaction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493567.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4D imaging / Anatomy / CT segmentation / Cardiac dynamics / Computed radiography / Computed tomography / Computer software / Data sets / Heart / Hemodynamics / Lungs / Medical imaging / Medical treatment planning / Pneumodyamics, respiration / Radiation treatment / Tissues / biological organs / biological tissues / cardiology / computerised tomography / deformable models / image segmentation / lung / medical image processing / pneumodynamics
  •  go-up   go-down


10. Ernst S, Sanchez-Quintana D, Ho SY: Anatomy of the Pericardial Space and Mediastinum: Relevance to Epicardial Mapping and Ablation. Card Electrophysiol Clin; 2010 Mar;2(1):1-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Related to the fibrous pericardium overlying the posterior wall of the left atrium is the esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 28770727.001).
  • [ISSN] 1877-9190
  • [Journal-full-title] Cardiac electrophysiology clinics
  • [ISO-abbreviation] Card Electrophysiol Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Average tumor size was 10.5 cm (4-28 cm).
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Of the remaining 33, median tumor size shrank to 55 mm.
  • Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection).
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 26 patients were excluded because of V<sub>20</sub> > 30% (n=10), overdose to the esophagus (n=8) and brachial plexus (n=2), comorbidity (n=3), or patient refusal (n=3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Dennie T, Alberti D, Oliver K, LoConte N, Mulkerin D, Wilding G, Holen K, Fleming R, Bowen C, O'Neill V: A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors.
  • One pt had breast cancer and the remainder had non- colorectal GI malignancies (esophagus, hepatobiliary, and pancreas).
  • CONCLUSIONS: The regimen of CapOx and L has efficacy in the treatment of solid tumors with established responsiveness to fluoropyrimidines or Ox.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V, Squires M, Fazal L, Judson I: A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors.
  • Exposure of solid tumour cell lines to AT9283 in vitro induces an "aurora inhibitory" phenotype.
  • An additional 4 patients received at least six cycles of therapy (squamous cell carcinoma of the lung, adenocarcinoma of the esophagus and colorectal carcinoma [2]) with a best response of stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.
  • PM00104 has shown broad in vitro and in vivo anti-tumor activity (IC<sub>50</sub> ≤ 10<sup>-8</sup> M) with an acceptable toxicology profile.
  • METHODS: The aim of this phase I study was to assess the safety profile, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), recommended dose (RD), pharmacokinetics (PK), relationship between PK and pharmacodynamics (PD) and anti-tumor activity of PM00104 administered as a 24-hour i.v. infusion q3w.
  • Five pts developed DLTs: 2 pts at 5000 μg/m<sup>2</sup> (grade 4 thrombocytopenia/neutropenia and grade 3 nausea/vomiting in 1 pt; and grade 3 nausea in 1 pt); 1 at 4000 μg/m<sup>2</sup> (grade 4 neutropenia/thrombocytopenia and grade 3 asthenia); 1 at 3200 μg/m<sup>2</sup> (grade 3 tumor pain) and 1 at 266 μg/m<sup>2</sup> (grade 3 transaminase increase).
  • At the RD 6 more pts have been included in order to further evaluate the safety profile and anti-tumor activity.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.
  • CONCLUSIONS: PM00104 has shown an acceptable safety profile with signs of anti-tumor activity in pts with advanced malignancies when administered as a 24-hour i.v. infusion q3w.
  • PM00104 is also being evaluated with other administration schedules as monotherapy and in combination with other anti-tumor agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wade FM, Pavlakis N, Receveur I, Leibman S, Smith GS: The role of cancer Nurse coordinator in foregut malignancy: Workload and costing considerations in the Australian setting. J Clin Oncol; 2009 May 20;27(15_suppl):e20559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20559 Background: Foregut (esophageal and gastric) malignancy (FM) encompasses a number of diseases with poor outlook and complex and often morbid treatment.
  • Further, the CNC is pivotal in ensuring that benchmarks regarding intervals from diagnosis, to multidisciplinary assessment to treatment commencement are met.
  • The number of cancers arising from the esophagus or esophagogastric junction was 135 (62%), stomach 78 (36%) and small bowel 5 (2%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Koh Y, Kim H, Lee H, Lee K, Oh D, Kim J, Im S, Kim T, Kim W, Bang Y: KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):10558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience.
  • Tumor DNA was extracted to investigate the mutation status of KITexon 9, exon 11, PDGFRA exon 12 and 18.
  • Location of primary disease included stomach (33), small bowel (34), rectum (10), esophagus (1), and omentum/mesentery (7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ruhstaller T, Pless M, Schuller JC, Kranzbühler H, von Moos R, Moosmann P, Rauch D, Montemurro M, Schneider PM, Hess V: Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol; 2009 May 20;27(15_suppl):4570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06).
  • We investigated the safety and feasibility of adding cetuximab to neoadjuvant chemoradiation of locally advanced esophageal cancer.
  • METHODS: Pts with resectable, locally advanced squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the thoracic esophagus or gastroesophageal junction (staged by EUS, CT and PET scan) were treated with 2 cycles of induction chemotherapy (docetaxel 75mg/m2, cisplatin 75mg/m2 q3w and weekly cetuximab 250mg/m2), followed by concomitant chemo- immuno-radiation therapy (CIRT: docetaxel 20mg/m2, cisplatin 25mg/m2 and cetuximab 250mg/m2 weekly five times concomitant with 45 Gy radiotherapy in 25 fractions); followed by surgery 4-8 weeks later.
  • CONCLUSIONS: Adding cetuximab to preoperative chemoradiation for esophageal cancer is safe and feasible in a community-based multicenter setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963079.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. De Vita F, Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G, Ciardiello F: A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). J Clin Oncol; 2009 May 20;27(15_suppl):4546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC).
  • METHODS: Eligibility criteria: resectable, locally advanced (uT3 or uN1, T4 if deemed resectable) squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus; staged by EUS, CT and PET scan; age 18-70y; PS <2; normal organ functions.All pts received induction treatment with C at a starting dose of 400 mg/m<sup>2</sup> and further weekly infusion at a maintenance dose of 250 mg/m<sup>2</sup> and 4 cycles of FOLFOX-4 every two weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963011.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Bogoevski D, Schurr PG, Koenig AM, Busch P, Kutup A, Izbicki JR: Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas? J Clin Oncol; 2009 May 20;27(15_suppl):e15640

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas?
  • : e15640 Background: The objective of this study was to investigate whether limited resection of the oesophagogastric junction can be successfully used in the treatment of the patients with early oesophageal carcinomas.
  • METHODS: A total of 111 patients with early oesophageal cancer (57 adenocarcinomas, 54 squamous cell carcinomas) had surgical resection with systematic lymphadenectomy (41 thoracoabdominal-TA, 52 transhiatal-TH and 18 with limited resection of the oesophagogastric junction- LROGJ).
  • None of the 43 patients with high grade intraepithelial neoplasia (HGIEN) or oesophageal carcinoma limited to the mucosa had lymphatic spread, as compared with 15 of 68 (22.1%) with affection of the submucosa.
  • Multifocal neoplasia was detected in three patients with SCC HGIEN (30%) but not in AC HGIEN!
  • Nine out of 44 (20.4%) patients with early SCC had multifocal neoplasia, compared to 6 out of 53 (11.3%) patients in AC (p=0.322).
  • The sensitivity of the preoperative tumour dept staging (endoscopic ultra sound - EUS; and CT) was astonishing low (only 50% for cT1b), as was the specificity (66.7% for cT1a and only 87.5% for cT1b).
  • On multivariate analysis, only histological tumor type (AC) was independent predictor of survival.
  • CONCLUSIONS: Considering the limitations and pitfalls of endoscopic and classical resectional procedures, the quest for alternative and "patient tailored" treatment in patients with early oesophageal carcinoma carries on.
  • A valuable alternative can be the limited resection of the oesophago-gastric junction under sparing of the healthy oesophagus and stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962740.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kelsen D, Jhawer M, Ilson D, Tse A, Randazzo J, Robinson E, Capanu M, Shah MA: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):4512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The addition of BEV to chemotherapy has improved survival in several solid tumors, and has demonstrated encouraging activity in GE cancer (Shah et al, JCO 2006).
  • RESULTS: Pt enrollment has completed: median age 57(range 29-74), median KPS 80% (70-100), M:F 32:12, gastric/GEJ/esophagus 22:17:5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bjerregaard JK, Schønnemann KR, Jensen HA, Vestermark LW, Hansen TP, Pfeiffer P: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Localisation of primary was: Esophagus 10%, GE junction 64%, gastric 26%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Pre- and on-treatment tumor biopsies in select pts and plasma samples in all pts are analyzed for GSK089 effects on direct and downstream drug targets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI: A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: AGC (esophagus, gastric, hepatocellular) patients (pts) with adequate organ function, performance status (ECOG 0-1), and 0-1 prior chemotherapy regimens are eligible for this phase 1 study to determine the MTD of V.
  • Tumor biopsy pre-Rx and at D13 are being done for TGFβ and survivin expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Iwase H, Shimada M, Tsuzuki T, Hirashima N, Goto H: Concurrent chemoradiotherapy for locally advanced cervical esophageal carcinoma: A phase II study of oral fluoropyrimidine agents (UFT, S-1) plus cisplatin with radiotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):6043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy for locally advanced cervical esophageal carcinoma: A phase II study of oral fluoropyrimidine agents (UFT, S-1) plus cisplatin with radiotherapy.
  • : 6043 Background: Carcinoma of the cervical esophagus is a highly virulent disease.
  • We evaluated concurrent chemoradiotherapy using an oral fluoropyrimidine (UFT, S-1) and cisplatin in patients with locally advanced cervical esophageal carcinoma.
  • Four patients had stage II tumors and 16 had stage III tumors.
  • Complete response (CR) was attained in all 4 patients with stage II tumors.
  • CONCLUSIONS: Chemoradiotherapy with an oral fluoropyrimidine (UFT, S-1) plus cisplatin is convenient, tolerable, and effective, and it is a promising nonsurgical management option for patients with locally advanced cervical esophageal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961907.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • METHODS: Patients with advanced solid tumors received carboplatin on day 1, paclitaxel on days 1, 8, 15 and capecitabine orally twice a day on days 8-21, every 4 weeks.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • Accepted indications are uni- and multifocal tumors smaller than 3 cm without suspicious findings in the axilla, furthermore SNB is indicated in patients with large ductal carcinoma in situ (>2 cm) and/or with assumed microinvasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


28. Nader D, Ketterl P, Kelly D, Flynn J, Stark JJ, Staren ED, Braun DP: Intratumoral chemotherapy as an adjunct to endobronchial brachytherapy. J Clin Oncol; 2009 May 20;27(15_suppl):7591

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intratumoral CTx consisted of CPt (1 mg/ml; 0.5-2.0 ml/session) injected into the entire visible tumor through a flexible 21 gauge needle through the bronchoscope.
  • In the other 2 pts, necrotic tissue occupying < 10 and 20% of the airway, cytologically negative for tumor was seen.
  • This approach offers the possibility of superior local tumor control while reducing toxicity to normal lung and esophagus as compared to conventional external beam radiation therapy modalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Horiike A, Morota M, Nishimura T, Yamamoto N: Radiotherapy (RT) dose escalation study with concurrent cisplatin and S-1 in patients with inoperable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The target volume of RT included primary tumor and metastatic node only and elective nodal irradiation was not performed.
  • Dose constraints to the organs at risk were: the lung, V20 < 30%; the esophagus, mean dose < 34 Gy and V55 < 30%; the spinal cord, max dose < 50 Gy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963318.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Horgan AM, Darling G, Wong R, Visbal A, Guindi M, Jonker D, Liu G, Hornby J, Xu W, Knox JJ: Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial.
  • : e15550 Background: Locally advanced esophageal cancer (LAEC) has a 5-year survival of < 30 %.
  • METHODS: Pts with LAEC of the thoracic esophagus or gastroesophageal junction, ECOG PS 0,1 and surgical candidates treated with: preoperative Irinotecan (65mg/m<sup>2</sup> initially, ammended to 50mg/m<sup>2</sup>) + Cisplatin (30mg/m<sup>2</sup>) on weeks 1,2,4,5,7,8 + concurrent conformal radiotherapy (50Gy/25 fractions) on weeks 4-8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962341.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Yoshii T, Tamai S, Aoyama N, Minamide J, Takagi S, Motohashi O, Nakayama N, Nishimura K, Takata K, Kameda Y: Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer.
  • : e15569 Background: When a tumor invades to the muscularis mucosa or submucosal layer (T1a-MM or T1b, in Japan), cSt I esophageal cancer(EC) has 10-50%.
  • Endoscopic mucosal resection (EMR), which conserves the esophagus, is a minimally invasive and attractive therapeutic modality for such pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962323.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lordick F, Meyer Zum Büschenfelde C, Thuss-Patience P, Röthling N, Geinitz H, Budach V, Schumacher G, Friess H, Siewert JR, Peschel C: Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):e15507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • All pts had locally advanced SCC (uT2-4, cNx, cM0-1a) of the cervical (n=1), the upper (n=5) or the distal (n=7) esophagus.
  • The anti-tumor activity of this regimen is promising and is being further investigated in an ongoing phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962237.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Jain S, Gupta T, Reenadevi P, Agarwal J, Laskar SG, Shrivastava SK: Patterns of failures after definitive conformal radiation therapy for head and neck cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e17037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrent or persistent tumor volume (Vf) was defined using positron imaging tomography (PET) and surgical-pathologic findings, and analyzed using dose-volume histograms.
  • Two patients were detected to have distant metastases and two developed second malignancies, one out-field and other marginal with upper esophagus carcinoma at gradient zone of previous radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Alcedo J, Ferrández A, Arenas J, Sopeña F, Ortego J, Sainz R, Lanas A: Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus; 2009 May 01;22(3):239-248

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28200121.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Saranovic D, Djuric-Stefanovic A, Ivanovic A, Masulovic D, Pesko P: Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types. Dis Esophagus; 2005 Sep 01;18(4):230-238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203894.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yu J Sr, Han D, Zhong X, Mu D, Fu Z, Zhan G B, Zhang L, Zhang W: The optimal threshold of &lt;sup&gt;18&lt;/sup&gt;F-FLT PET and &lt;sup&gt;18&lt;/sup&gt;F-FDG PET to estimate the length of gross tumor volume in patients with squamous cell carcinoma of the thoracic esophagus verified by pathological examination. J Clin Oncol; 2009 May 20;27(15_suppl):e15665

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The optimal threshold of <sup>18</sup>F-FLT PET and <sup>18</sup>F-FDG PET to estimate the length of gross tumor volume in patients with squamous cell carcinoma of the thoracic esophagus verified by pathological examination.
  • : e15665 Background: To determine the optimal method of using 3-deoxy-3-<sup>18</sup>F-fluorothymidine (FLT) positron emission tomography (PET) to estimate gross tumor length in esophageal carcinoma, and compared with that of <sup>18</sup>F- fluorodeoxyglucose(FDG) PET.
  • METHODS: Twenty patients with esophageal squamous cell carcinoma treated with radical surgery were enrolled and detected by FLT PET, eighteen of them underwent FDG PET scan.
  • Gross tumor volumes (GTVs) were delineated using seven different methods with FLT PET: visual interpretation, standardized uptake value (SUV) 1.3, SUV 1.4, SUV 1.5, and 20% of maximum standard uptake value (SUVmax), 25% SUVmax,30% SUVmax, on FLT PET imaging, and three different methods with FDG PET: visual interpretation, SUV 2.5, and 40%SUVmax on FDG PET imaging.
  • The length of tumors on FLT PET scan were measured and recorded as L<sub>FLTvis</sub>, L<sub>FLT1.3</sub>, L<sub>FLT1.4</sub>, L<sub>FLT1.5</sub>, L<sub>FLT20%</sub>, L<sub>FLT25%</sub>, and L<sub>FLT30%</sub>, and FDG PET scan were measured and recorded as L<sub>FDGvis</sub>, L<sub>FDG2.5</sub>, and L<sub>FDG40%</sub>, respectively, and compared with the length of gross tumor in the resected specimen measured by pathological examination (L<sub>Path</sub>).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962763.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Manickavasagam K, Servarayan CM, Rao S, Chandramohan A: Hedgehog signaling: Gli2 and its influence in squamous esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling: Gli2 and its influence in squamous esophageal cancer.
  • This study is to determine the expression pattern and the extent of Hh-signaling molecule(Gli2) in squamous cell carcinoma of oesophagus.
  • METHODS: A prospective immunohistochemical experimental study was done to identify the expression of Gli2 in 64 cases of squamous cell carcinoma of oesophagus.
  • These findings can be used for better prognosis of the patients by using stem cell therapy and HH pathway inhibitors in the treatment for squamous cell carcinomas of oesophagus.
  • To the best of our knowledge, this is the first study of expression of Gli2 in squamous cell carcinoma of oesophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kwong DL, Law SY, Tong DK, Wong KH, Nicholls J: COX-2 inhibition in combination with preoperative chemoradiation for CA esophagus. J Clin Oncol; 2009 May 20;27(15_suppl):e15607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 inhibition in combination with preoperative chemoradiation for CA esophagus.
  • : e15607 Background: Squamous cell carcinoma of the thoracic esophagus (ESCC) is often diagnosed in advanced stage.
  • The pCR rate in primary tumor was 51.7% (15/29 patients) and pCR rate in lymph nodes was 65.4% (17/26 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Yang D, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ: Polymorphisms in epidermal growth factor (EGF) and proteinase activated receptor 1 (PAR-1) associated with tumor recurrence in localized adenocarcinoma (EA) of the esophagus treated with surgery alone. J Clin Oncol; 2009 May 20;27(15_suppl):4564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in epidermal growth factor (EGF) and proteinase activated receptor 1 (PAR-1) associated with tumor recurrence in localized adenocarcinoma (EA) of the esophagus treated with surgery alone.
  • : 4564 Background: Tumor angiogenesis is a well-recognized aspect of human cancer biology and is mediated at least in part by EGF and PAR-1, which in turn may impact the process of tumor growth and progression.
  • Systemic tumor recurrence after curative resection continues to be a significant problem in the management of patients with localized EA.
  • Further, it is being increasingly recognized that esophageal squamous cell carcinoma and EA are separate and distinct disease groups and need to be considered individually.
  • We therefore designed a large retrospective study of EA patients to identify novel molecular markers of prognosis to better define tumor stage and progression, and help to define novel targets, as well as surrogate-endpoints of disease progression and response to therapy.
  • METHODS: Between 1992 and 2005 normal esophageal tissue samples from 239 patients with localized EA treated with surgery alone were obtained at University of Southern California medical facilities.
  • 114 out of 239 (48%) patients had tumor recurrence, with a probability of 5-year recurrence of 0.62 ± 0.04.
  • RESULTS: PAR-1 -506 ins/del (p-value=0.003; log-rank test) and EGF +61 A>G (p-value=0.034; log-rank test) are adverse prognostic markers in univariate analysis.
  • CONCLUSIONS: This study supports the role of functional EGF and PAR-1 polymorphisms as independent prognostic markers in localized EA and may therefore help to identify patient subgroups at high risk for tumor recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963056.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Liu L Jr, Huang Y, Guo J, Wang ZH, Song DG: Correlation between FDG PET/CT and the expression of Ki-67, MMP-2, micro-vessel density (MVD), and pathological grading in squamous cell carcinoma of the esophagus. J Clin Oncol; 2009 May 20;27(15_suppl):e15556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between FDG PET/CT and the expression of Ki-67, MMP-2, micro-vessel density (MVD), and pathological grading in squamous cell carcinoma of the esophagus.
  • : e15556 Background: Variable uptake of 18FDG has been noticed in positron emission tomography (PET) studies of patients with esophageal squamous cell carcinoma (ESCC).
  • The aim of the present study was to determine if <sup>18</sup>F-FDG PET/CT standardized uptake value (SUV) could quantitatively reflect tumor proliferation, invasion and angiogenesis, and to reveal the relationship between SUV and pathological grading of ESCC.
  • 18FDG uptake was semiquantitatively measured by SUV.Tumour sections were HE stained to determine the pathological grading,and were stained by immunohistochemistry for proliferation marker (Ki67), invasion marker (MMP-2), and angiogenic marker (CD34).
  • RESULTS: Among all the 47 cases,there were 13 well- differentiated squamous cell tumors, 16 moderately differentiated tumors and 18 poorly differentiated tumors,45 of 47 tumors revealed FDG. accumulation in primary tumor foci confirmed by subsequently histopathologically.
  • The mean SUV of well-differentiated, moderately differentiated and poorly differentiated tumors were 9.787±1.477, 12.313±0.479, 15.053±2.147 respectively, and a significant difference could be determined between them by statistical analysis(P=0.000).
  • SUV could reflect proliferation and invasion potential of tumor.
  • However, there is no significant correlation between SUV and MVD, thus it could not reflect tumor angiogenesis in ESCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP).
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.
  • 18 PTS have completed NA therapy; Grade 4 toxicity includes anemia (1), lymphopenia (2); grade 3 toxicity includes esophagitis (1), pneumonia (1), wound infection (1), anastomotic leak (2), esophageal fistula (1), bowel obstruction (1), fatigue (1), hyperbilirubinemia (1), elevated ALT, AST (1 & 2, respectively), hypoalbuminemia (3), OXP hypersensitivity (2) & leucopenia (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Braghetto I, Papapietro K, Csendes A, Gutierrez J, Fagalde P, Diaz E, Rodriguez A, Undurraga F: Nonesophageal side-effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with long-segment Barrett's esophagus. Dis Esophagus; 2005 Aug 01;18(3):140-145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonesophageal side-effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with long-segment Barrett's esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203867.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ng T, DiPetrillo T, Suntharalingam M, Fontaine J, McNulty B, Akerman P, Chen W, Horiba MN, Burrows W, Safran H: Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase II trial.
  • A phase II study was therefore initiated to evaluate the pathologic response rate of neoadjuvant PPX, cisplatin and radiation for patients with esophageal cancer.
  • METHODS: Eligible patients had pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or GE junction with no evidence of distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962301.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Batra U, Doval DC, Talwar V, Sharma JB, Sherali R: TIP regimen in metastatic or recurrent esophageal cancer: An Indian experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15664

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIP regimen in metastatic or recurrent esophageal cancer: An Indian experience.
  • : e15664 Background: Currently, there is no standard regimen for metastatic or recurrent upper or middle squamous cell esophageal cancer.
  • We therefore undertook this study to test the first-line combination of TIP regimen (Paclitaxel, Ifosfamide and cisplatinum) in patients with metastatic carcinoma of the esophagus.
  • METHODS: This study evaluated the efficacy, tolerability and toxicity profile of the TIP regimen in patients with metastatic or recurrent carcinoma of the upper or middle squamous cell carcinoma of esophagus.
  • The median time to tumor progression was 7 months and the median survival was 13 months (range 2-36 months).
  • CONCLUSIONS: The combination of Paclitaxel, Ifosfamide and Cisplatinum has significant activity in metastatic or recurrent esophageal cancer.
  • The ease of administration, cost effectiveness and suitable safety profile makes it an ideal first line regimen in metastatic esophageal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Dvorak K, Fass R, Dekel R, Payne CM, Chavarria M, Dvorakova B, Bernstein H, Bernstein C, Garewal H: Esophageal acid exposure at pH ≤ 2 is more common in Barrett's esophagus patients and is associated with oxidative stress. Dis Esophagus; 2006 Oct 01;19(5):366-372

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal acid exposure at pH ≤ 2 is more common in Barrett's esophagus patients and is associated with oxidative stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203923.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. De Rezende L, Lucendo AJ, Álvarez-Argüelles H: Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques. Dis Esophagus; 2007 Oct 01;20(5):436-443

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203918.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tomas D, Tomić K, Bekavac-Bešlin M, Jukić Z, Belicza M, Krušlin B: Primary glomangioma of the esophagus mimicking esophageal papilloma. Dis Esophagus; 2006 Jun 01;19(3):208-211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glomangioma of the esophagus mimicking esophageal papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203903.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Altorjay Á, Szilágyi A, Sárkány Á, Varga I, Jachymczyk G, Paál B, Kecskés G: Synchronous spontaneous perforation of the esophagus and a duodenal ulcer. Dis Esophagus; 2005 Aug 01;18(3):207-210

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous spontaneous perforation of the esophagus and a duodenal ulcer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203888.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients.
  • : 10567 Background: The objective of this study is to investigate the characteristics and survival rate of patients with Gastrointestinal Stromal Tumor (GIST) associated with other primary malignancies.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Sharma K, Mohanti BK, Sharma DN, Rath GK, Julka PK, Muzumder S: Pattern of palliative care, pain management, and referral trends in developing countries: Still far from optimum. J Clin Oncol; 2009 May 20;27(15_suppl):e20694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maximum (60%) patients were of head and neck cancers followed by oesophagus (14%), lung (10%) and others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Deschamps C, Wang K: Dear colleagues, readers and contributors to Diseases of the Esophagus. Dis Esophagus; 2007 Feb 01;20(1):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dear colleagues, readers and contributors to Diseases of the Esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203914.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern.
  • : 4557 Background: Pre-operative chemoradiotherapy (CRT) followed by surgical resection is a standard treatment option for pts with resectable esophageal or GE junction (GEJ) carcinomas (CA).
  • We conducted this study to evaluate this regimen in pts with esophageal and GEJ CA.
  • METHODS: This is a single arm, open label pilot study combining cetuximab with XRT for pts with resectable esophageal and GEJ CA.
  • Key eligibility criteria are: squamous cell (SC)or adenoCA of the esophagus or GEJ, ECOG PS 0-2, clinical stage II -IVa, and eligible for esophagectomy.
  • RESULTS: Patient characteristics (n=40): median age 65 years (range, 54-82); 92% male; PS 0/1 63%/32%; esophageal/GEJ 65%/35%; adenoCA/SC 78%/22%; 36 pts have completed cetuximab and radiation and 26 pts have undergone esophagectomy.
  • CONCLUSIONS: Cetuximab and XRT results in pCR's in pts with esophageal and GEJ CA (rate of pCR 13/36), including patients with either SC or adenoCA histologies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Feinstein TM, Agrawal S, Stoller RG, Egorin MJ, Argiris A: Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 17 evaluable pts, there were no objective responses; 9 pts had stable disease: salivary gland cancer (3), thyroid (2), sarcoma (1), unknown primary (1), esophagus (1), and NSCLC (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. McAlindon ME, Sanders DS, Sidhu R: Capsule endoscopy: 10 years on and in the frontline. Frontline Gastroenterol; 2010 Jul;1(2):82-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The production of different capsule endoscopes to examine the oesophagus, small bowel and colon now means that almost all of the gut can be examined using this technology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2009 Jan;104(1):219-27 [19098872.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1054-9 [15578294.001]
  • [Cites] Scand J Gastroenterol. 2008;43(4):497-505 [18365916.001]
  • [Cites] Z Gastroenterol. 2009 Apr;47(4):339-46 [19358059.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):42-8 [16429354.001]
  • [Cites] World J Gastroenterol. 2007 Aug 28;13(32):4372-8 [17708614.001]
  • [Cites] Endoscopy. 2009 Jul;41(7):618-37 [19588292.001]
  • [Cites] Endoscopy. 2008 May;40(5):414-21 [18302080.001]
  • [Cites] Endoscopy. 2009 Sep;41(9):762-6 [19662592.001]
  • [Cites] Endoscopy. 2007 Dec;39(12):1041-5 [18072053.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):606-12 [17611915.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):62-70 [15990821.001]
  • [Cites] Hepatology. 2008 May;47(5):1595-603 [18435461.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):49-58 [16429355.001]
  • [Cites] Am J Gastroenterol. 2006 May;101(5):954-64 [16696781.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):983-8 [16803698.001]
  • [Cites] World J Gastroenterol. 2008 Jul 14;14(26):4137-41 [18636657.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Aug;21(8):952-4 [19404201.001]
  • [Cites] Dig Liver Dis. 2006 Sep;38(9):696-8 [16920049.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):613-5 [17516287.001]
  • [Cites] World J Gastroenterol. 2008 Mar 7;14(9):1313-7 [18322940.001]
  • [Cites] Med Bull (Ann Arbor). 1957 May;23(5):178-80 [13433948.001]
  • [Cites] Endoscopy. 2007 Mar;39(3):208-15 [17385105.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):902-9 [18355824.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):539-45 [16564850.001]
  • [Cites] Endoscopy. 2007 May;39(5):455-8 [17516353.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 May;6(5):536-44 [18242145.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):920-36 [18407270.001]
  • [Cites] J Clin Gastroenterol. 2006 Sep;40(8):688-91 [16940879.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):963-70 [17058158.001]
  • [Cites] Acta Radiol. 2006 Dec;47(10):1008-16 [17135001.001]
  • [Cites] Endoscopy. 2004 Jul;36(7):656-8 [15243892.001]
  • [Cites] Am J Gastroenterol. 2010 Jun;105(6):1240-8; quiz 1249 [20029412.001]
  • [Cites] Dig Liver Dis. 2007 Feb;39(2):140-5 [16965945.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2407-18 [16279893.001]
  • [Cites] World J Gastroenterol. 2008 Sep 14;14(34):5269-73 [18785278.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):525-32 [17459025.001]
  • [Cites] Gastrointest Endosc. 2008 Aug;68(2):267-72 [18378233.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1047-53 [17058174.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):671-6 [18356113.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):275-9 [18389444.001]
  • [Cites] Gut. 2003 May;52(5):742-6 [12692062.001]
  • [Cites] Clin Radiol. 2009 Apr;64(4):341-52 [19264177.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):385-90 [16680639.001]
  • [Cites] Gut. 2008 Jan;57(1):125-36 [18094205.001]
  • [Cites] Dig Dis Sci. 2007 May;52(5):1382-6 [17357836.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):971-7 [17058159.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):55-61 [15990820.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1624-31 [17459022.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2):253-9 [18640676.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Oct 1;22(7):595-604 [16181299.001]
  • [Cites] Radiology. 2008 Apr;247(1):64-79 [18372465.001]
  • [Cites] J Gastrointestin Liver Dis. 2009 Sep;18(3):273-8 [19795019.001]
  • [Cites] N Engl J Med. 2009 Jul 16;361(3):264-70 [19605831.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):661-70 [18550005.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1697-717 [17983812.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1999 Jan;9(1):13-27 [9834314.001]
  • [Cites] World J Gastroenterol. 2009 Apr 28;15(16):1934-42 [19399924.001]
  • [Cites] Endoscopy. 2005 Oct;37(10 ):1051-4 [16189789.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41 [15704047.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):643-53 [14988816.001]
  • (PMID = 28839553.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Cassier PA, Blesius AA, Perol D, Ray-Coquard I, Adenis A, Bui B, Bertucci F, Rios M, Le Cesne A, Blay J: Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10551 Background: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains unknown.
  • We sought to assess the outcome of patients with locally advanced primary GIST tumors without metastases treated with IM in the neoadjuvant setting within the prospective BFR14 phase III trial.
  • Twenty patients were PS 0 or 1, primary tumor sites were: small intestine (n=7), peritoneum (n=7), rectum (n=4), stomach (n=4), esophagus (n=2), and pelvis (n=1).
  • Nine of the 25 patients underwent surgical resection of the primary tumor after a median of 7.3 (range 3.4-12.1) months of treatment with IM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963947.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Feilchenfeldt JW, Capanu M, Farooki A, Sully D, Miron B, Power DG, Jhawer M, Ilson DH, Kelsen DP, Shah MA: Diabetes mellitus (DM), serum glucose, and outcome in gastroesophageal (GE) cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their diagnosis is predictive of early recurrence following resection of colorectal cancer and of increased treatment related toxicity in localized breast cancer.
  • METHODS: 211 patients with GE cancer enrolled on 3 localized (2 esophagus, 1 gastric) and 4 metastatic consecutive prospective clinical trials (3 gastric, 1 esophagus) were examined.
  • Diagnosis of DM was based on clinical data, random glucose or fasting-glucose levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962769.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Boers JE, Meeuwissen H, Methorst N: HER2 status in 146 gastroesophageal carcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridisation methods (FISH and SISH). J Clin Oncol; 2009 May 20;27(15_suppl):e15555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15555 Background: In the industrialized world, the incidence of adenocarcinomas of the distal esophagus/gastric cardia is increasing rapidly and though the incidence of carcinomas of the gastric body / antrum are decreasing they still represent a significant health problem.
  • Several reports claim a significant HER2-positivity in gastro-esophageal adenocarcinomas.
  • METHODS: HER2 status was examined in gastro-esophageal carcinomas, comparing SP3 (Labvision) and 4B5 (Ventana) immunohistochemistry (IHC), conventional dual probe HER2 FISH (DAKO), and SISH (Ventana) in a single Dutch institution.
  • RESULTS: IHC was carried out on biopsies of 146 patients with adenocarcinomas of the esophagus (n=44), gastric cardia (n=28), body (n=24) and antrum (n=50).
  • Heterogenous HER2- positivity with partial staining/amplification was present in 73% of the adenocarcinomas, occasionally with only a tumor area of 10-20% showing positivity.
  • HER2-amplification was present in 27% of esophageal and 18% in gastric cardia carcinomas (resulting in 24% amplification of tumors of the esophago-gastric region).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Zhang P, Yang J, Hunt M, Mageras G: Dose correction strategy for the optimization of volumetric modulated arc therapya). Med Phys; 2010 Jun;37(6Part2):2441-2444

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical cases for brain, prostate, paraspinal, and esophagus are utilized to evaluate the method.
  • Applying dose correction during optimization saves planners 2-4 h in average in treatment planning, and has a positive impact on plan quality, evidenced by a noticeably higher PTV mean dose: 2.1%, 2.4%, 0.5%, and 9.3% of the corresponding prescription dose in the brain, esophagus, prostate, and paraspinal cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28513907.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brain / Cancer / Computer simulation / Dose-volume analysis / Dosimetry / Intensity modulated radiation therapy / Medical treatment planning / Multileaf collimators / Optimization / Radiation treatment / Therapeutic applications, including brachytherapy / biological organs / dose calculation / dosimetry / optimisation / radiation therapy / treatment planning / volumetric arc modulated therapy
  •  go-up   go-down


59. Tangen M, Andresen SJ, Moum B, Hauge T: [Stent insertion as palliation of cancer in the esophagus and cardia]. Tidsskr Nor Laegeforen; 2006 Jun 8;126(12):1607-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stent insertion as palliation of cancer in the esophagus and cardia].
  • [Transliterated title] Palliasjon med stent ved kreft i oesophagus og cardia.
  • BACKGROUND: The insertion of self-expanding metal stents (SEMS) for palliation of dysphagia in patients with malignant stenosis of the esophagus and cardia, is a well-established procedure.
  • The aim of this retrospective study was to evaluate the results of esophageal stenting in terms of functioning, need of retreatment and survival after stenting.
  • PATIENTS AND METHODS: 37 patients with unresectable esophageal and cardial carcinoma treated with SEMS between January 1997 and May 2004 were retrospectively analysed.
  • Tumor ingrowth or overgrowth was primarily treated with argon plasma coagulation (APC).
  • CONCLUSION: Insertion of SEMS in patients with inoperable carcinoma in esophagus and cardia should be regarded as a safe procedure.
  • [MeSH-major] Cardia. Esophageal Neoplasms / therapy. Palliative Care / methods. Stents. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Deglutition Disorders / etiology. Deglutition Disorders / therapy. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Esophagoscopy. Female. Humans. Male. Metals. Middle Aged. Prosthesis Implantation / adverse effects. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770371.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


60. Nguyen NT, Reavis KM, El-Badawi K, Hinojosa MW, Smith BR: Minimally invasive surgical enucleation or esophagogastrectomy for benign tumor of the esophagus. Surg Innov; 2008 Jun;15(2):120-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgical enucleation or esophagogastrectomy for benign tumor of the esophagus.
  • Experience in surgical resection of benign tumor of the esophagus is limited.
  • Authors performed a chart review of 5 patients who underwent minimally invasive surgical resection of benign esophageal tumor.
  • Main outcome measures included operative approaches, tumor's location and size, and outcomes.
  • Tumor location were middle esophagus (n = 1), distal esophagus (n = 2), and gastroesophageal junction (n = 2).
  • Surgical pathology showed leiomyoma in 3 patients and gastrointestinal stromal tumor in 2 patients.
  • Tumor size ranged from 1.1 to 10.5 cm.
  • There has been no tumor recurrence at a mean follow-up of 14 months.
  • Minimally invasive surgical enucleation or esophagogastrectomy for benign esophageal tumor is feasible and safe.
  • The optimal approaches should be tailored based on the location and size of the tumor.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrectomy / methods. Minimally Invasive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492731.001).
  • [ISSN] 1553-3506
  • [Journal-full-title] Surgical innovation
  • [ISO-abbreviation] Surg Innov
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Boran C, Sengul N, Balaban YH, Gürel S: Multinodular leiomyoma of the esophagus with internodular hydropic degeneration and bulbous serosal protrusions similar to cotyledonoid uterine leiomyoma. Dis Esophagus; 2007;20(2):187-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multinodular leiomyoma of the esophagus with internodular hydropic degeneration and bulbous serosal protrusions similar to cotyledonoid uterine leiomyoma.
  • Leiomyoma is the most common benign tumor of the esophagus, and usually occurs as a solitary mass.
  • We report a case of esophageal leiomyoma which shows multinodular growth pattern with bulbous serosal protrusions.
  • The patient was a 26-year-old woman who had an esophageal ulcerated mass near the gastroesophageal junction.
  • Based on the clinical diagnosis, total gastrectomy with distal esophagectomy was performed.

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439606.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Lee SY, Chan WH, Sivanandan R, Lim DT, Wong WK: Recurrent giant fibrovascular polyp of the esophagus. World J Gastroenterol; 2009 Aug 7;15(29):3697-700
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent giant fibrovascular polyp of the esophagus.
  • Giant fibrovascular polyps of the esophagus and hypopharynx are rare benign esophageal tumors.
  • They arise most commonly in the upper esophagus and may, rarely, originate in the hypopharynx.
  • Even though they are benign, they may be lethal due to either bleeding or, rarely, asphyxiation if a large polyp is regurgitated.
  • The polyps may not be well visualized on endoscopy and imaging plays a vital role in aiding diagnosis as well as providing important information for pre-operative planning, such as the location of the pedicle, the vascularity of the polyp and the tissue elements of the mass.
  • We review the recent literature and report a case of a 61-year-old man with a recurrent giant esophageal fibrovascular polyp with illustrative contrast barium swallow, CT and intra-operative images, who required several surgeries via a combination of endoscopic, trans-oral, trans-cervical, trans-thoracic and trans-abdominal approaches.
  • [MeSH-major] Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Polyps / surgery
  • [MeSH-minor] Esophagus / pathology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 2000;13(4):324-7 [11284984.001]
  • [Cites] Yonsei Med J. 2001 Apr;42(2):264-6 [11371118.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2598-604 [12452402.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):485-7 [12683881.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):781-7 [8610549.001]
  • [Cites] Eur Radiol. 1998;8(2):264-9 [9477279.001]
  • [Cites] Am J Otolaryngol. 2007 Mar-Apr;28(2):115-7 [17362817.001]
  • [Cites] Abdom Imaging. 2005 Nov-Dec;30(6):653-5 [16132431.001]
  • [Cites] Ann Thorac Surg. 2006 Jan;81(1):393-6 [16368421.001]
  • [Cites] Eur Radiol. 2006 Mar;16(3):764-6 [16470418.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):725-7 [16683893.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):749-51 [16891825.001]
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):109-10 [10024391.001]
  • (PMID = 19653354.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC2721250
  •  go-up   go-down


63. Solerio D, Gasparri G, Ruffini E, Camandona M, De Angelis C, Raggio E, Dei Poli M: Giant fibrovascular polyp of the esophagus. Dis Esophagus; 2005;18(6):410-2
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant fibrovascular polyp of the esophagus.
  • Giant fibrovascular polyps are uncommon benign esophageal tumors almost always originating from the cervical esophagus, frequently from the upper esophageal sphincter.
  • Only fiberoptic endoscopy suggested the correct diagnosis because the mass fluctuated endoluminally with the spasm of vomiting.
  • A giant fibrovascular polyp was observed and excised.
  • If a malignant or benign extensive intramural tumor had been identified, a total esophagectomy would have been performed.
  • In our opinion the possibility of the presence of a fibrovascular polyp should always be considered in the presence of an undetermined esophageal mass, and in these cases a left cervical incision is the preferred surgical access.
  • Once the correct diagnosis is established, a major esophageal resection should always be avoided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336614.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Asteriou C, Konstantinou D, Lalountas M, Kleontas A, Setzis K, Zafiriou G, Barbetakis N: Nine years experience in surgical approach of leiomyomatosis of esophagus. World J Surg Oncol; 2009;7:102
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine years experience in surgical approach of leiomyomatosis of esophagus.
  • BACKGROUND: Leiomyomas of esophagus, although rare, are the most frequent benign tumors of esophagus.
  • Aim of this study is the presentation of 7 patients with esophageal leiomyomas who underwent surgical treatment during a 9-year period.
  • METHODS: Epidemiological data (sex, age), the presenting symptoms, diagnostic examinations, tumor location, histopathological findings and the safety and efficacy of surgical resection are analyzed and assessed.
  • In 3 cases the tumor was located at the lower esophagus, while in the other 4 cases, the leiomyoma was found at the median third of esophagus.
  • None of them received resection of part of the esophagus.
  • The mean diameter of the resected tumors was 4.3 cm.
  • CONCLUSIONS: Esophageal leiomyoma is a benign tumor, which causes symptoms only if its size becomes large.
  • [MeSH-major] Esophageal Neoplasms / surgery. Leiomyomatosis / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Jan;46(1):88-92 [10601061.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):44-9 [11756913.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2002 Apr 10;82(7):456-8 [12133514.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):856-62 [12190103.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):78-81 [17505413.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):394-6 [12408774.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):257-62 [7670685.001]
  • [Cites] Radiology. 1996 May;199(2):533-6 [8668807.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1122-5 [15797036.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4 Suppl):S43-8 [12297748.001]
  • (PMID = 20030817.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804581
  •  go-up   go-down


65. Solbakken AM, Hovde Ø, Glomsaker T: [The use of stents in benign oesophageal conditions]. Tidsskr Nor Laegeforen; 2005 Aug 25;125(16):2175-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of stents in benign oesophageal conditions].
  • [Transliterated title] Bruk av stent ved benigne tilstander i oesophagus.
  • BACKGROUND: In recent years, self-expanding stents have been used to treat benign perforations and strictures of the oesophagus.
  • METHODS: We conducted a PubMed search of literature from January 1st 1993 to February 7th 2005 on the use of self-expanding stents in benign oesophageal conditions.
  • RESULTS: Only case reports and minor series are published in the literature; further studies are needed in order to define the future role of stents in benign disease.
  • Present experience indicates that self-expanding metal stents can be used in benign perforations of the oesophagus, provided that the stent is removed once the perforation has healed.
  • When stents are used in benign strictures, a high number of complications should be expected; the literature is more ambiguous as to whether or not this procedure should be recommended.
  • [MeSH-major] Esophageal Perforation / therapy. Esophageal Stenosis / therapy. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138129.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Metals; 0 / Plastics
  • [Number-of-references] 81
  •  go-up   go-down


66. Kong J, Stairs DB, Lynch JP: Modelling Barrett's oesophagus. Biochem Soc Trans; 2010 Apr;38(2):321-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modelling Barrett's oesophagus.
  • Barrett's oesophagus is the replacement of normal squamous oesophageal epithelium with an intestinalized columnar epithelium.
  • Although some insight has been gained as to what Barrett's oesophagus is, how this columnar epithelium emerges from within a stratified squamous epithelium remains an unanswered question.
  • We have sought to determine whether oesophageal keratinocytes can be trans-differentiated into Barrett's oesophagus cells.
  • Using an Affymetrix microarray, we found unexpectedly that gene-expression patterns in the Barrett's oesophagus were only slightly more similar to the normal small intestine than they were to the normal oesophagus.
  • Thus gene-expression patterns suggest significant molecular similarities remain between Barrett's oesophagus cells and normal squamous oesophageal epithelium, despite their histological resemblance with intestine.
  • Retroviral-mediated Cdx2 (Caudal-type homeobox 2) expression in immortalized human oesophageal keratinocytes engineered with human telomerase reverse transcriptase (EPC2-hTERT cells) could be established transiently, but not maintained, and was associated with a reduction in cell proliferation.
  • However, when combined with treatments that induce chromatin remodelling, there was a significant induction of Barrett's oesophagus-associated genes.
  • Studies are ongoing to determine whether other intestinal transcription factors, either alone or in combination, can provoke greater intestinalization of oesophageal keratinocytes.
  • We conclude that, on the basis of gene-expression patterns, Barrett's oesophagus epithelial cells may represent an intermediate between oesophageal keratinocytes and intestinal epithelial cells.
  • Moreover, our findings suggest that it may be possible to induce Barrett's oesophagus epithelial cells from oesophageal keratinocytes by altering the expression of certain critical genes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298176.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068366; United States / NCI NIH HHS / CA / CA138998; United States / NCI NIH HHS / CA / P01 CA098101; United States / NIDDK NIH HHS / DK / P30-DK50306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


67. Chella B, Nosotti M, Baisi A, Lattuada E, Mazzone A, Santambrogio L: Unusual presentation of a transparietal cavernous hemangioma of the esophagus. Dis Esophagus; 2005;18(5):349-54
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of a transparietal cavernous hemangioma of the esophagus.
  • Hemangiomas are tumors of vascular origin and represent less than 3% of benign neoplasm of the esophagus.
  • A malignancy could not be excluded by a complete work-up, including esophagogram, endoscopic biopsies, CT scan, esophageal endoscopic ultrasonography, PET and thoracoscopic biopsies.
  • Only after partial esophagectomy with laparoscopic gastric mobilization was histological diagnosis obtained.
  • In fact, on microscopic observation of the specimen, the neoplasm appeared to be a cavernous hemangioma of the esophageal submucosa with transparietal extension.

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197539.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ba-Ssalamah A, Zacherl J, Noebauer-Huhmann IM, Uffmann M, Matzek WK, Pinker K, Herold C, Schima W: Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdom Imaging; 2009 Jan-Feb;34(1):3-18
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedicated multi-detector CT of the esophagus: spectrum of diseases.
  • Its ability to cover a large volume in a very short scan time, and in a single breath hold with thin collimation and isotropic voxels, allows the imaging of the entire esophagus with high-quality multiplanar reformation and 3D reconstruction.
  • Proper distention of the esophagus and stomach (by oral administration of effervescent granules and water) and optimally timed administration of intravenous contrast material are required to detect and characterize disease.
  • In contrast to endoscopy and double-contrast studies of the upper GI tract, CT provides information about both the esophageal wall and the extramural extent of disease.
  • Preoperative staging of esophageal carcinoma appears to be the main indication for MDCT.
  • In addition, MDCT allows detection of other esophageal malignancies, such as lymphoma and benign esophageal tumors, such as leiomyma.
  • A diagnosis of rupture or fistula of the esophagus can be firmly established using MDCT.
  • Furthermore, miscellaneous esophageal conditions, such as achalasia, esophagitis, diverticula, and varices, are incidental findings and can also be visualized with hydro-multi-detector CT.
  • Multi-detector CT is a valuable tool for the evaluation of esophageal wall disease and serves as an adjunct to endoscopy.
  • [MeSH-major] Esophageal Diseases / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media. Esophageal Neoplasms / pathology. Esophageal Neoplasms / radiography. Humans. Imaging, Three-Dimensional. Neoplasm Staging. Radiographic Image Interpretation, Computer-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653787.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


69. Huang Q, Hardie LJ: Biomarkers in Barrett's oesophagus. Biochem Soc Trans; 2010 Apr;38(2):343-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's oesophagus.
  • Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy.
  • The majority of Barrett's oesophagus patients remain undiagnosed in the general population.
  • In order to develop a tool to screen for Barrett's oesophagus in the primary care setting, minimally invasive sampling methods coupled with immunocytology-based biomarkers are currently being assessed.
  • Biomarkers are also being developed to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, utilizing brush cytology combined with FISH (fluorescence in situ hybridization), and to assess therapeutic success and risk of complication during photodynamic therapy.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / genetics. Biomarkers / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298180.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C11347
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Pharmacological
  • [Number-of-references] 50
  •  go-up   go-down


70. Shaheen NJ, Richter JE: Barrett's oesophagus. Lancet; 2009 Mar 7;373(9666):850-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus.
  • Barrett's oesophagus is a metaplastic change of the lining of the oesophagus, such that the normal squamous epithelium is replaced by specialised or intestinalised columnar epithelium.
  • The disorder seems to be a complication of chronic gastro-oesophageal reflux disease, although asymptomatic individuals might also be affected, and it is a risk factor for the development of oesophageal adenocarcinoma, a cancer with rapidly increasing incidence in developed societies.
  • We discuss the molecular changes necessary for the development of Barrett's oesophagus and its progression to cancer, and new strides in both the endoscopic detection of the lesion and the treatment of dysplastic disease.
  • Also, we assess the effectiveness of efforts to screen patients at risk of Barrett's oesophagus, and whether such efforts avert cancer death.
  • We conclude with a discussion of future directions for research, focusing on treatment of early neoplasia, and modifications of current practices to show our evolving understanding of this condition.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus. Esophageal Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269522.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 139
  •  go-up   go-down


71. Bonino JA, Sharma P: Barrett's esophagus. Curr Opin Gastroenterol; 2006 Jul;22(4):406-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • PURPOSE OF REVIEW: Barrett's esophagus continues to be a popular topic among clinicians and researchers alike.
  • Population based studies have finally been undertaken to better identify subset populations at high risk of developing Barrett's esophagus, and possible better tolerated alternatives to standard endoscopy for cost-effective screening.
  • In addition, several studies over the past year have marked a transition from identifying those with Barrett's esophagus and in need of intensive surveillance, to an increasing number of novel treatment therapies that are now primed to move from experimental protocols to clinical practice.
  • RECENT FINDINGS: Obesity's role as a risk factor for the development of Barrett's esophagus continues to be better defined.
  • Various disorders affecting the motility of the gastrointestinal tract, such as celiac sprue and scleroderma, and their relationship with Barrett's esophagus development are becoming more widely recognized.
  • The use of endoscopic mucosal resection and photodynamic therapy for treatment of dysplastic Barrett's esophagus continues to gain increased acceptance, with an additional wealth of supportive data for its effectiveness becoming available.
  • SUMMARY: The past year has brought many advances in the epidemiology and endoscopic treatment of those with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus. Endoscopy, Gastrointestinal / methods. Esophagectomy / methods. Mass Screening / methods. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760758.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


72. Binderup MD, Jensen VJ, Busch S: [Lymphangioma of the oesophagus]. Ugeskr Laeger; 2009 Jan 26;171(5):312-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphangioma of the oesophagus].
  • Lymphangiomas are benign tumours that rarely occur in the oesophagus.
  • A sessile, 5-mm polyp was seen at gastroscopy.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymphangioma / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176159.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


73. Bird-Lieberman EL, Fitzgerald RC: Barrett's esophagus. Gastroenterol Clin North Am; 2008 Dec;37(4):921-42, x
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • Barrett's esophagus is an important step in the pathway to esophageal adenocarcinoma.
  • Since most patients with Barrett's esophagus are undiagnosed and patients present with advanced adenocarcinoma de novo, prognosis for this disease remains poor.
  • To identify those people with Barrett's esophagus who are at particular risk many new technologies are being developed.
  • [MeSH-major] Barrett Esophagus

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028325.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U105365007; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


74. Bonino JA, Sharma P: Barrett's esophagus. Curr Opin Gastroenterol; 2005 Jul;21(4):461-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • PURPOSE OF REVIEW: Significant advances have been made over the past year to identify individuals with Barrett's esophagus, who are at increased risk of malignant transformation.
  • We summarize some of the important advances in that regard including: improved understanding in areas of epidemiology of those with Barrett's esophagus, identification of the pathways responsible for dysplastic and metaplastic development, selection of patient populations who would most benefit from surveillance protocols, and identification of biomarkers signifying progression of metaplastic changes.
  • RECENT FINDINGS: Barrett's esophagus is being better recognized in patients presenting with extra-esophageal symptoms of gastroesophageal reflux such as chronic cough and asthma.
  • Recent reports from some surgical series further suggest the importance of gastric and even duodenal reflux in the etiology of esophageal metaplastic development.
  • There appears to be a select group of individuals with familial predilection for the development of Barrett's esophagus.
  • Retrospective studies continue to show apparent survival benefit in individuals with Barrett's esophagus undergoing surveillance endoscopy.
  • Endoscopic ablative therapy may provide clinicians an attractive alternative to surgical resection in individuals with high-grade esophageal dysplasia and early adenocarcinoma.
  • SUMMARY: The past year has brought many advances in the epidemiology, pathogenesis, surveillance, and treatment of those with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus. Precancerous Conditions
  • [MeSH-minor] Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / pathology. Humans. Intestinal Mucosa / pathology. Metaplasia / pathology. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930989.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


75. Kauer WK, Stein HJ, Dittler HJ, Siewert JR: [Barrett's esophagus]. Chirurg; 2005 Mar;76(3):258-62
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus].
  • [Transliterated title] Barrett-Osophagus Verhältnis zwischen Ausmass der intestinalen Metaplasie, Funktion des unteren Osophagussphinkters und Säure- bzw. Gallereflux.
  • INTRODUCTION: It is widely accepted that long segments of Barrett's esophagus are caused by end-stage gastroesophageal reflux disease (GERD), but little is known about the correlation of severity of GERD and extent of metaplasia.
  • METHODS: Twenty normal volunteers and 142 patients with different extent of intestinal metaplasia (39 with intestinal metaplasia limited to the esophagogastric junction, 48 with short segments of Barrett's esophagus, and 55 with long segments) underwent manometry and combined pH-bilirubin monitoring.
  • RESULTS: The extent of intestinal metaplasia correlated to the exposition of gastric and duodenal juice in the esophagus and inversely with a competent lower esophageal sphincter.
  • [MeSH-major] Barrett Esophagus / diagnosis. Bilirubin / analysis. Duodenogastric Reflux / complications. Esophagogastric Junction / pathology. Esophagogastric Junction / physiopathology. Esophagus / pathology. Gastric Acidity Determination. Gastroesophageal Reflux / complications. Manometry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Esophageal Neoplasms / physiopathology. Female. Humans. Male. Metaplasia. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Risk Factors. Statistics as Topic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1990 Oct;108(4):769-77; discussion 777-8 [2218890.001]
  • [Cites] Ann Surg. 1992 Jul;216(1):35-43 [1632700.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):572-80 [10047662.001]
  • [Cites] Thorax. 1961 Mar;16:36-41 [13712529.001]
  • [Cites] Arch Surg. 2001 Nov;136(11):1267-73 [11695971.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):547-53; discussion 553-4 [10457313.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):113-22 [9834337.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):522-30; discussion 530-2 [9351720.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):107-11 [8419690.001]
  • [Cites] Ann Med. 1999 Feb;31(1):46-50 [10219713.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):98-103; discussion 103-4 [7818006.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1007-10 [11490786.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):344-51 [10716147.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):554-60 [11922546.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):43-8 [12364989.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Jul;9(3):270-8 [9263345.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1192-9 [8898632.001]
  • [Cites] Surgery. 1995 Jun;117(6):699-704 [7778033.001]
  • (PMID = 15580449.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


76. Dilemmas in managing Barrett's oesophagus. Drug Ther Bull; 2006 Sep;44(9):69-72
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dilemmas in managing Barrett's oesophagus.
  • In the UK, oesophageal adenocarcinoma accounts for over 7,000 deaths per year and its incidence is rising.
  • One risk factor for this cancer is Barrett's oesophagus.
  • Of people with Barrett's oesophagus, about 1% per year develop adenocarcinoma, around 30-125 times the rate in the general population.
  • So it has been suggested that people with reflux should be screened for Barrett's oesophagus, and those with the condition should be kept under surveillance to detect dysplasia or adenocarcinoma in the early stages.
  • Here we discuss the problems in managing patients with Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009567.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 72
  •  go-up   go-down


77. Włodarczyk J: [Barret esophagus--molecular biology]. Przegl Lek; 2008;65(2):73-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barret esophagus--molecular biology].
  • Increasing incidence of adenocarcinoma of the esophagus is nowadays observed in western countries.
  • Estimation of the unique molecules may, in the future, lead to early diagnostics of pathological changes in the Barret esophagus and identification of the patient at risk from cancerogenesis.
  • The aim of this study is to explain terminology of Barret esophagus, basis of histopatology, diagnostics and to show molecules which have crucial significance in cancerogenesis.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Esophageal Neoplasms / prevention & control. Genetic Markers
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Oncogenes / genetics. Risk Factors. Terminology as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663904.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 62
  •  go-up   go-down


78. Palanivelu C, Rangarajan M, John SJ, Annapoorni S, Senthilkumar S: A rare cause of intermittent dysphagia: giant fibrovascular polyp of the proximal esophagus. J Coll Physicians Surg Pak; 2007 Jan;17(1):51-2
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of intermittent dysphagia: giant fibrovascular polyp of the proximal esophagus.
  • Fibrovascular polyps account for only 0.5-1% of all benign esophageal tumors and causes intermittent dysphagia.
  • Investigations revealed a submucosal tumor of the proximal esophagus causing luminal compromise.
  • [MeSH-major] Deglutition Disorders / etiology. Esophageal Diseases / complications. Polyps / complications

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204222.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


79. Blacha MM, Sloots CE, Van Munster IP, Wobbes T: Dysphagia caused by a fibrovascular polyp: a case report. Cases J; 2008;1(1):334
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysphagia caused by a fibrovascular polyp: a case report.
  • Barium contrast study of the esophagus and esophagoscopy demonstrated a fibrovascular polyp.
  • This, almost 10 cm benign esophageal tumor, was removed surgically by a cervical esophagotomy.
  • A fibrovascular polyp is a rare benign tumor of the esophagus, which, however, may give serious complications as asphyxia resulting from laryngeal obstruction leading to sudden death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Sep;18(9):1005-9 [16894315.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):725-7 [16683893.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1196-201 [16181840.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1979-82 [10588130.001]
  • [Cites] J Gastroenterol. 2004 Dec;39(12):1205-9 [15622487.001]
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):109-10 [10024391.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2598-604 [12452402.001]
  • [Cites] Am J Forensic Med Pathol. 2005 Sep;26(3):275-81 [16121086.001]
  • (PMID = 19019249.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2602996
  •  go-up   go-down


80. Hongo M: [Preface: Recent perspectives of the Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1319-22
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preface: Recent perspectives of the Barrett's esophagus].
  • As the prevalence of reflux esophagitis is increasing in Japan, due to increased amount of energy intake and improved hygiene with the reduced H. pylori infection, the number of patients having Barrett's esophagus is also increasing.
  • In the Western countries, adenocarcinoma of the esophagus is rapidly increasing among the white elder male, where the reflux esophagitis is more common.
  • Terminology of Barrett's esophagus is still confusing.
  • Recent proposal of endoscopic evaluation of Barrett's esophagus is based on the endoscopic findings, not histologic findings.
  • In the development of adenocarcinoma of the esophagus, several steps of genetic abnormalities might be involved.
  • We still do not know whether we may experience an increase of adenocarcinoma of the esophagus in Japan or not.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Esophagitis, Peptic / complications. Esophagoscopy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101216.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


81. Shaligram A, Dugar N, Capper R: Perforation of cervical oesophagus. J Laryngol Otol; 2005 Jan;119(1):51-3
MedlinePlus Health Information. consumer health - Foreign Bodies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforation of cervical oesophagus.
  • Spontaneous perforation of the oesophagus is an uncommon condition that almost invariably affects the thoracic oesophagus.
  • We present an unusual case of perforation of the cervical oesophagus, in which an unsuspected ingested foreign body was ultimately found to be responsible.
  • [MeSH-major] Esophageal Diseases / etiology. Esophagus. Foreign Bodies / complications

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807967.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Aoki T, Kouzu T, Miyazaki S, Okazaki Y, Ochiai T: [The operation of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1443-7
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The operation of Barrett's esophagus].
  • The purpose of operation in Barrett's esophagus is to protect against esophageal acid exposure.
  • In Western countries antireflux surgery is positive because Barrett's esophagus is recognized as premalignancy.
  • Thus if cancer is not detected in Barrett's esophagus, it is difficult to accept surgery.
  • [MeSH-major] Barrett Esophagus / surgery
  • [MeSH-minor] Animals. Combined Modality Therapy. Enzyme Inhibitors / therapeutic use. Esophagoscopy. Esophagus / pathology. Esophagus / surgery. Gastric Acidity Determination. Gastroesophageal Reflux / drug therapy. Gastroesophageal Reflux / surgery. Humans. Metaplasia / surgery. Mucous Membrane / pathology. Mucous Membrane / surgery. Proton Pump Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101237.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors
  • [Number-of-references] 13
  •  go-up   go-down


83. Li J, Omo A, Liu L, Liu L, Tang Y, Pan T: Huge benign mesenchymoma in pharynx-esophagus. Ann Thorac Surg; 2006 Jun;81(6):2283-5
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge benign mesenchymoma in pharynx-esophagus.
  • Benign mesenchymoma is an uncommon neoplastic disease and its occurrence in pharynx-esophagus is even more rarely reported.
  • The origin of this tumor was in the pharynx-esophagus, and complete excision was achieved through a laterocervical approach.
  • [MeSH-major] Esophageal Neoplasms / pathology. Mesenchymoma / pathology. Pharyngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731171.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Badreddine RJ, Wang KK: Barrett esophagus: an update. Nat Rev Gastroenterol Hepatol; 2010 Jul;7(7):369-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett esophagus: an update.
  • Many developments have been made in the field of Barrett esophagus that have tremendous clinical implications.
  • There are new definitions of Barrett esophagus that have had an immediate clinical impact on cancer risk and screening.
  • Of interest is the definition by the British Society of Gastroenterology, which does not require the presence of intestinal metaplasia for a diagnosis of Barrett esophagus.
  • Indeed, the crucial role that transcription factors have in the pathogenesis of Barrett esophagus has been clarified.
  • Improved characterization of the molecular mechanisms underlying Barrett esophagus is an incentive to undertake more basic science research in this field.
  • This Review discusses the advances in understanding of the pathogenesis, diagnosis and treatment of Barrett esophagus.
  • [MeSH-major] Barrett Esophagus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517288.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


85. Waxman I, Konda VJ: Mucosal ablation of Barrett esophagus. Nat Rev Gastroenterol Hepatol; 2009 Jul;6(7):393-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal ablation of Barrett esophagus.
  • The management of Barrett esophagus is evolving with the emergence of new endoscopic technologies.
  • However, with the advent of endoscopic ablative therapies for Barrett esophagus, the treatment paradigm has shifted.
  • Patients with high-grade dysplasia and intramucosal carcinoma are increasingly offered esophagus-sparing therapies.
  • One or more modalities may be used to eradicate the entire region of affected esophagus totally.
  • Success of treatment may be gauged by complete remission of cancer, dysplasia, or Barrett esophagus.
  • In addition to procedure-related complications, the risk of residual Barrett esophagus or subsquamous Barrett esophagus remains to be addressed.
  • [MeSH-major] Barrett Esophagus / pathology. Barrett Esophagus / surgery. Endoscopy, Gastrointestinal. Mucous Membrane / pathology. Mucous Membrane / surgery
  • [MeSH-minor] Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):182
  • (PMID = 19488071.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  •  go-up   go-down


86. Palanivelu C, Rangarajan M, Senthilkumar R, Annapoorni S, Jategaonkar PA: Thoracoscopic management of benign tumors of the mid-esophagus: a retrospective study. Int J Surg; 2007 Oct;5(5):328-31
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopic management of benign tumors of the mid-esophagus: a retrospective study.
  • Benign esophageal tumors are rare conditions.
  • Now, increasingly more surgeons are using minimally invasive techniques to treat these benign mid-esophageal lesions.
  • We have managed 12 patients with benign tumors of the mid-esophagus from 1995 to 2007 in our institute.
  • Leiomyomas and GISTs, respectively, are the commonest benign tumors of the esophagus.
  • Tumors more than 5 cm have to be enucleated, and thoracotomy has been the traditional approach to these lesions.
  • [MeSH-major] Esophageal Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Leiomyoma / surgery. Thoracostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638600.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Canto MI: Endomicroscopy of Barrett's Esophagus. Gastroenterol Clin North Am; 2010 Dec;39(4):759-69
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endomicroscopy of Barrett's Esophagus.
  • Both probe-based and endoscope-based systems have been applied to many gastrointestinal disorders, including Barrett's esophagus (BE) and associated neoplasia.
  • It has proven high accuracy for prediction of high-grade neoplasia and cancer.
  • In vivo imaging of both flat BE and mucosal lesions can influence diagnosis and thereby impact upon decision making regarding tissue sampling and endoscopic therapy.
  • This article discusses the scientific literature related to clinical use of CLE for BE, the techniques for performing CLE in the esophagus, and the potential future directions for CLE in BE and esophageal cancer diagnosis and treatment.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagoscopy / methods. Microscopy, Confocal / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21093753.001).
  • [ISSN] 1558-1942
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


88. Dapri G, Himpens J, Ntounda R, Alard S, Dereeper E, Cadière GB: Enucleation of a leiomyoma of the mid-esophagus through a right thoracoscopy with the patient in prone position. Surg Endosc; 2010 Jan;24(1):215-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enucleation of a leiomyoma of the mid-esophagus through a right thoracoscopy with the patient in prone position.
  • BACKGROUND: Leiomyoma is the most common benign esophageal neoplasm.
  • Preoperative work-up showed the presence of 50 x 28-mm leiomyoma of the middle esophagus, without satellite lymph nodes.
  • The muscular layer of the mid-esophagus was opened by coagulating hook.
  • The gastrograffin swallow on postoperative day 2 showed good clearance of the esophagus and absence of leak, hence the patient was allowed a liquid diet.
  • Benign pathology was confirmed.
  • CONCLUSION: Thoracoscopy in the prone position permits the surgeon to reach the esophagus under excellent working conditions, despite an only partially deflated lung.
  • [MeSH-major] Esophageal Neoplasms / surgery. Leiomyoma / surgery. Thoracoscopy / methods
  • [MeSH-minor] Esophagus / surgery. Female. Humans. Middle Aged. Prone Position

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517189.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Holzinger F, Giachino D, Karamitopoulou-Diamantis E, Birrer S: [Unexpected tumour of the distal esophagus]. Chirurg; 2007 Jun;78(6):548-51
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unexpected tumour of the distal esophagus].
  • [Transliterated title] Unerwarteter, intraoperativer Befund im Bereiche des distalen Osophagus.
  • We report a patient with unexpected intraoperative diagnosis of a big leiomyoma of the distal esophagus found during laparoscopic repair of a typ III hiatal hernia complicated by Cameron ulcer and chronic anaemia.
  • Laparoscopic transhiatal enucleation of the tumour was performed with closure of the myotomy, Nissen fundoplication, and crural repair.
  • Briefly, the literature of leiomyoma of the esophagus is reviewed with special regard to different therapeutic strategies.
  • [MeSH-major] Esophageal Neoplasms. Leiomyoma
  • [MeSH-minor] Esophagus / pathology. Female. Follow-Up Studies. Fundoplication. Hernia, Hiatal / complications. Hernia, Hiatal / surgery. Humans. Laparoscopy. Middle Aged. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4258-60 [16015702.001]
  • [Cites] Am J Surg. 1946 Nov;72(5):745-7 [21003138.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jan;15(1):35-43 [12813687.001]
  • [Cites] Cancer. 1976 Nov;38(5):2166-77 [991129.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):257-62 [7670685.001]
  • [Cites] Br J Surg. 1992 Jul;79(7):643 [1643473.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):1008-10 [12467830.001]
  • [Cites] Gastrointest Endosc. 1990 Jul-Aug;36(4):342-50 [2210274.001]
  • [Cites] Am J Gastroenterol. 1962 Dec;38:639-52 [13943914.001]
  • (PMID = 17096108.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Bampton PA, Schloithe A, Bull J, Fraser RJ, Padbury RT, Watson DI: Improving surveillance for Barrett's oesophagus. BMJ; 2006 Jun 3;332(7553):1320-3
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving surveillance for Barrett's oesophagus.
  • PROBLEM: A retrospective audit of surveillance for Barrett's oesophagus 1996-2001 identified the need to improve adherence to guidelines for the endoscopic surveillance of patients with Barrett's oesophagus.
  • Prospective audit of the effect of introducing local guidelines and Barrett's oesophagus surveillance officers, 2003-2005.
  • All adult patients diagnosed with Barrett's oesophagus were included.
  • KEY MEASURES FOR IMPROVEMENT: Proportions of patients in a Barrett's oesophagus surveillance programme who had appropriate time intervals between follow-up endoscopies and who had appropriate numbers of biopsies collected at endoscopy.
  • Surveillance coordinators for Barrett's oesophagus were introduced to manage the process according to a clinical protocol designed for each patient.
  • LESSONS LEARNT: Disseminating guidelines and results of an audit on endoscopic surveillance in Barrett's oesophagus had no effect on practice.
  • [MeSH-major] Barrett Esophagus / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2003 May 15;17(10):1319-24 [12755845.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] J Gastrointest Surg. 2000 Mar-Apr;4(2):115-6 [10885953.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Med J Aust. 2002 Feb 18;176(4):155-7 [11913914.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Med J Aust. 2004 Feb 2;180(3):139-40 [14748680.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Feb;16(2):171-5 [15075990.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [CommentIn] BMJ. 2006 Jun 24;332(7556):1512 [16793832.001]
  • [CommentIn] BMJ. 2006 Jun 24;332(7556):1511-2 [16793826.001]
  • (PMID = 16740562.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1473087
  •  go-up   go-down


91. Kuwano H, Sohda M, Kato H, Miyazaki T, Kimura H: [Clinical outline of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1372-8
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outline of Barrett's esophagus].
  • Barrett's esophagus is one of the important gastrointestinal disease in Europe and the United States.
  • Recently, realization of Barrett's esophagus is attentioned in Japan, because increasing of reflux esophagitis for westernization of eating habit, living habit and aging of the population.
  • In this section, we present general consideration and clinical research of Barrett's esophagus.
  • We expect Barrett's esophagus will gradually increase near the future and need to research abundantly about controversial point of Barrett's esophagus.
  • We also think it is important to accumulate intensively the clinical data of Barrett's esophagus patients.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Esophagus / pathology. Genes, Tumor Suppressor. Helicobacter Infections. Helicobacter pylori. Humans. Metaplasia. Oncogenes. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101224.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


92. Watanabe M, Sekine K, Hori Y, Shiraishi Y, Maeda T, Honma D, Miyata G, Saijo Y, Yambe T: Artificial esophagus with peristaltic movement. ASAIO J; 2005 Mar-Apr;51(2):158-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artificial esophagus with peristaltic movement.
  • In this study, we have developed an artificial esophagus simulating peristaltic movement with the use of a nickel-titanium shape memory alloy (NiTi-SMA) actuator.
  • In an animal experiment using a goat, the cervical esophagus was resected over a length of approximately 20 cm.
  • The artificial esophagus was anastomosed with the remaining cervical esophagus.
  • The entire contraction of the artificial esophagus was similar to the esophageal peristaltic movement observed by x-ray examination in humans.
  • The results showed the possibility that the artificial esophagus could function as an artificial esophagus having peristaltic movement.
  • [MeSH-major] Artificial Organs. Esophagus. Peristalsis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839441.001).
  • [ISSN] 1058-2916
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Rahili A, D'Amata G, Avallone S, Piche M, Benchimol D: Concomitant leiomyoma and leiomyosarcoma of the oesophagus. J Exp Clin Cancer Res; 2005 Sep;24(3):487-91
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant leiomyoma and leiomyosarcoma of the oesophagus.
  • Leiomyosarcoma of the oesophagus is a malignant tumor that originates from smooth muscle cells.
  • The filiation between oesophageal leiomyoma and leiomyosarcoma is controversial, with few cases reported in literature.
  • The authors describe un uncommon situation with the simultaneous presence of a leiomyoma and a leiomyosarcoma of the oesophagus in a 75 year-old man, which have been successfully treated with surgical resection.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Leiomyoma / diagnosis. Leiomyosarcoma / diagnosis

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270537.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies of the cardiac mucosa and Barrett's oesophagus.
  • Confusion regarding the diagnosis of Barrett's oesophagus exists because of a false dogma that cardiac mucosa is normally present in the gastro-oesophageal junctional region.
  • Recent data indicate that the only normal epithelia in the oesophagus and proximal stomach are squamous epithelium and gastric oxyntic mucosa.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • Histopathological precision cannot be matched by any other modality and can convert the confusion that exists regarding diagnosis of Barrett's oesophagus to complete lucidity in a manner that is simple, accurate, and reproducible.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology. Gastric Mucosa / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


95. Somerville M, Garside R, Pitt M, Stein K: Surveillance of Barrett's oesophagus: is it worthwhile? Eur J Cancer; 2008 Mar;44(4):588-99
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of Barrett's oesophagus: is it worthwhile?
  • OBJECTIVE: To assess the cost-effectiveness of surveillance of Barrett's oesophagus.
  • PATIENTS: One thousand 55-year-old men with Barrett's oesophagus.
  • INTERVENTION: Surveillance programme: endoscopy and biopsy at 3 yearly intervals for non-dysplastic Barrett's oesophagus; low-grade dysplasia yearly; high grade-dysplasia 3 monthly.
  • For people with Barrett's oesophagus in England and Wales, a value of pound6.5 million is placed on acquiring perfect information about surveillance of Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophageal Neoplasms / economics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272361.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


96. Canto MI: Barrett's esophagus. Gastrointest Endosc Clin N Am; 2005 Jan;15(1):83-92, ix
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • Esophageal cancer staging is a widely accepted indication for endoscopic ultrasonography (EUS).
  • The evaluation of Barrett's esophagus (BE) with EUS is indicated only when there is high-grade dysplasia or a concern for malignancy in an endoscopic lesion.
  • This article discusses the scientific evidence for the use of EUS in BE or early esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Barrett Esophagus / ultrasonography. Endosonography / methods. Esophageal Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555953.001).
  • [ISSN] 1052-5157
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


97. Kawano T, Ogiya K, Nakamura M: [Progression and extending speed of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1350-5
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progression and extending speed of Barrett's esophagus].
  • Barrett's esophagus is one of the terminal manifestations of reflux esophagitis.
  • Although the typical Barrett's esophagus is very rare in Japan, the prevalence rate of short-segment Barrett's esophagus is extremely higher comparing with in western countries.
  • The discrepancy may be caused by the differences of criteria of short-segment Barrett's esophagus.
  • Observation of Barrett's mucosa in residual esophagus after esophagectomy is a useful method of considering the extension of Barrett's esophagus.
  • Short-segment Barrett's esophagus accompanied by gastro-esophageal reflux may show a rapid extension under some adequate conditions.
  • Large volume prospective studies are needed to clarify the extension speed of Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / pathology
  • [MeSH-minor] Disease Progression. Esophagus / pathology. Gastroesophageal Reflux / complications. Humans. Mucous Membrane / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101220.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


98. Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, Jankowski J: Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther; 2008 Feb 15;27(4):316-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality rates in patients with Barrett's oesophagus.
  • BACKGROUND: Patients with Barrett's oesophagus are at increased risk of oesophageal adenocarcinoma.
  • AIM: To assess the cause of death in patients with Barrett's oesophagus compared with the general population.
  • METHODS: Patients with Barrett's oesophagus were identified retrospectively in four hospitals in Leicestershire, UK using electronic endoscopy and histopathology records from 1997 to 2003.
  • The main disease areas that were responsible for this increase were oesophageal adenocarcinoma (n = 25, male SMR = 2171, 95% CI = 991-3351; female SMR = 1300, 95% CI = 26-2574), bronchopneumonia (n = 70, male SMR = 146, 95% CI = 55-236; female SMR = 436, 95% CI = 272-601) and ischaemic heart disease (n = 51, male SMR = 186, 95% CI = 97-2748; female SMR = 205, 95% CI = 105-306).
  • CONCLUSIONS: Patients with Barrett's oesophagus die more commonly of bronchopneumonia and ischaemic heart disease compared with oesophageal adenocarcinoma, and overall mortality in this group may be increased.
  • [MeSH-major] Barrett Esophagus / mortality. Esophageal Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2008 May;27(9):852-3; author reply 853-4 [18380800.001]
  • (PMID = 18062791.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ 4584
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Szumiło J, Dabrowski A, Zinkiewicz K, Chyzyńska M, Korobowicz E: Sarcomatoid carcinoma of the esophagus. Pol J Pathol; 2005;56(1):47-50
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the esophagus.
  • The authors present two rare cases of sarcomatoid carcinoma of the lower thoracic esophagus in a 73-year-old woman and a 42-year-old man.
  • The histogenesis, clinicopathological features and differential diagnosis of this unusual tumor are also discussed.
  • [MeSH-major] Carcinosarcoma / secondary. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Carcinoma, Giant Cell / diagnosis. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Female. Gastrointestinal Stromal Tumors / diagnosis. Humans. Leiomyosarcoma / diagnosis. Male. Melanoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921013.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


100. Sica GS, Sujendran V, Warren B, Maynard ND: Neurofibromatosis of the esophagus. Ann Thorac Surg; 2006 Mar;81(3):1138-40
MedlinePlus Health Information. consumer health - Neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis of the esophagus.
  • There have been previous reports suggesting an association between von Recklinghausen's neurofibromatosis and esophageal dysmotility.
  • We report the first case of true Recklinghausen's neurofibromatosis of the esophagus leading to end-stage pseudoachalasia.
  • The diagnosis and management of this condition is discussed together with the pathogenesis and pathology of this rare entity.
  • [MeSH-major] Esophageal Neoplasms / surgery. Neurofibromatoses / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488750.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement